Q4 2025 Neurocrine Biosciences Inc Earnings Call Transcript
Key Points
- Neurocrine Biosciences Inc (NBIX) reported a 22% year-over-year growth in total product sales, reaching over $2.8 billion in 2025.
- Ingrezza generated over $2.5 billion in revenue, marking a 9% year-over-year increase, driven by double-digit volume growth.
- The launch of Cronicity was successful, with over $300 million in net product sales and approximately 10% of the addressable patient population being prescribed the medication.
- Neurocrine Biosciences Inc (NBIX) has a strong cash position, increasing by approximately $700 million to $2.5 billion by the end of 2025.
- The company is advancing its pipeline with multiple phase 2 and phase 3 programs, including promising developments in neuropsychiatry and obesity treatments.
- Despite strong sales, Neurocrine Biosciences Inc (NBIX) is not providing specific sales guidance for Cronicity in 2026 due to market dynamics and learning curves.
- The company anticipates a 4% price decline for Ingrezza in 2026 due to formulary access improvements, which may impact revenue growth.
- There is uncertainty regarding the potential seasonality and early launch bolus effects on Cronicity's patient demand.
- The company faces challenges in expanding Cronicity's reach beyond endocrinologists to primary care providers and OBGYNs.
- Neurocrine Biosciences Inc (NBIX) is investing heavily in salesforce expansion and R&D, which may impact short-term profitability.
Hello and welcome everyone joining today's Neurocrine Biosciences fourth quarter and fiscal year 2025 earnings call.
At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question-and-answer session.
To register to ask a question at any time, please press star one on your telephone keypad.
Please note this call is being recorded. We are standing by if you should need any assistance, and it is now my pleasure to turn the meeting over to Todd Tusla, Vice President of Investor Relations. Please go ahead.
Happy Wednesday to everyone and welcome to Neocrine Biosciences 4th quarter and 2025 year-end earnings call. With me today are Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benovich, Chief Commercial Officer, Sanjay Kaswani, Chief Medical Officer, and for the first time, we are very pleased to be joined by Samir Sadanti, Vice President of Strategy and Corporate Development
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
